The budget lacks offensive efforts that shows that Sweden has the ambition to be a leading life science nation that invests in pharmaceuticals, states Lif further.

“Sweden needed a budget for long-term growth and major investments in innovation to meet the geopolitical challenges affecting the industry. We are pleased that previous statements about cost savings on pharmaceuticals have been toned down in the budget bill. What we lack is an understanding that investments in pharmaceuticals increase growth and productivity,” states Sofia Wallström, CEO of Lif.

The government also highlights the importance of access to medicines in order to achieve good treatment outcomes in healthcare and the promotion of clinical trials.

“To succeed in attracting clinical trials and other corporate investments, Sweden needs to invest in life science along the entire value chain. An ambitious use of new innovative medicines is important for patients and the efficiency of healthcare, as well as an engine for research and development,” comments Wallström.